HPCTC adopts biometric fingerprint tech to register patients

By Melissa Fassbender contact

- Last updated on GMT

HPCTC adopts biometric fingerprint tech to register patients
High Point Clinical Trials Center (HPCTC) has partnered with Verified Clinical Trials to help prevent duplicate enrollment in clinical trials.

According to the company, the technology will be used to select and qualify clinical trial patients at its North Carolina research facility.

If subjects participate in multiple clinical trials without sharing that information with the physicians running the trial, it can skew the data, thus putting the trial at risk in terms of data accuracy​,” Doug Copeland, Executive Vice President at High Point Clinical Trials Center, told us.

Verified Clinical Trials (VCT) helps protect against duplicate enrollment by using biometric fingerprint technology to register patients. The technology is designed for both early and late phase trials.

[The] system allows us to check to see if clients are doing multiple trials, thus helping ensure data integrity​,” explained Copeland.

Other sites across the US are registering their subjects with similar biometric fingerprint technology​. We compare our registered subjects with other programs in the database. It is a safe and highly effective way to register subjects and identify duplicates​.”

Copeland said the company evaluated a number of providers for the service, but felt Verified Clinical Trials was “the most comprehensive in both coverage (size of their database), technology and had the best ease of use​.”

(Feature image: iStock/IgorKozeev)

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers